The likelihood and nature of potential acute, sub-acute or long-term side-effects associated with<unk>  depends on the location of the tumour being treated and the type of<unk>  being used. Acute Acute side effects associated with<unk>  include localised bruising, swelling, bleeding, discharge or discomfort within the implanted region. These usually resolve within a few days following completion of treatment. Patients may also feel fatigued for a short period following treatment.<unk>  treatment for cervical or prostate cancer can cause acute and transient urinary symptoms such as urinary retention, urinary incontinence or painful urination (dysuria). Transient increased bowel frequency, diarrhoea, constipation or minor rectal bleeding, may also occur. Acute and subacute side effects usually resolve over a matter of days or a few weeks. In the case of permanent (seed)<unk>  for prostate cancer, there is a small chance that some seeds may migrate out of the treatment region into the bladder or urethra and be passed in the urine.<unk>  for skin cancer may result in a shedding of the outer layers of skin (desquamation) around the area of treatment in the weeks following therapy, which typically heals in 5–8 weeks. If the cancer is located on the lip, ulceration may occur as a result of<unk> , but usually resolves after 4–6 weeks. Most of the acute side effects associated with<unk>  can be treated with medication or through dietary changes, and usually disappear over time (typically a matter of weeks), once the treatment is completed. The acute side effects of HDR<unk>  are broadly similar to EBRT. Long-term In a small number of people,<unk>  may cause long-term side effects due to damage or disruption of adjacent tissues or organs. Long-term side effects are usually mild or moderate in nature. For example, urinary and digestive problems may persist as a result of<unk>  for cervical or prostate cancer, and may require ongoing management.<unk>  for prostate cancer may cause erectile dysfunction in approximately 15-30% of patients. However, the risk of erectile dysfunction is related to age (older men are at a greater risk than younger men) and also the level of erectile function prior to receiving<unk> . In patients who do experience erectile dysfunction, the majority of cases can successfully be treated with drugs such as Viagra. Importantly, the risk of erectile dysfunction after<unk>  is less than after radical prostatectomy.<unk>  for breast or skin cancer may cause scar tissue to form around the treatment area. In the case of breast<unk> , fat necrosis may occur as a result of fatty acids entering the breast tissues. This can cause the breast tissue to become swollen and tender. Fat necrosis is a benign condition and typically occurs 4–12 months after treatment and affects about 2% of patients.
Brachytherapy
Carboxytherapy
Irradiation
Organotherapy
Trepanning
Microwave thermotherapy
Radiation therapy
Chemoradiotherapy